Calando

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

People in the News

Premium

Timothy Triche

The CEO of Calando parent firm Arrowhead Research also said that the RNAi shop has restarted preclinical research and development — a notable departure from events in 2009 when the company stopped all such work and shuttered Calando's lab amid a cash crunch.

People in the News

Premium

John Rossi

Arrowhead's CEO said that the firm wants to accelerate enrollment in the study in order to meet its goal of completing the trial by year end.

As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.

The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.

Calando's management remains optimistic about deals in 2011. But some industry observers expect that it will take years of continued advancement in the RNAi field and a shift in its players' expectations before major deals are consummated.

Pages

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.